Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8251 to 8265 of 8905 results

  1. Clopidogrel in the treatment of non-ST-segment-elevation acute coronary syndrome (TA80)

    This guidance has been replaced by recommendations 1.3.4 to 1.3.8 in NICE guideline CG94 and by recommendation 1.3.18 in NICE guideline CG172.

    Withdrawn guidance

  2. Colorectal cancer (advanced) - irinotecan, oxaliplatin and raltitrexed (TA93)

    This guidance has been updated and replaced by NICE guideline NG151. The recommendations on raltitrexed have been withdrawn because its use is established clinical practice.

    Withdrawn guidance

  3. Targeted-release budesonide for treating primary IgA nephropathy (TA937)

    This guidance has been updated and replaced by NICE technology appraisal guidance 1128.

    Withdrawn guidance

  4. Statins for the prevention of cardiovascular events (TA94)

    This guidance has been updated and replaced by NICE guideline CG181.

    Withdrawn guidance

  5. Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer (TA885)

    This guidance has been updated and replaced by NICE technology appraisal guidance 939.

    Withdrawn guidance

  6. The use of autologous chondrocyte implantation for the treatment of cartilage defects in the knee joints (TA89)

    This guidance has been updated and replaced by NICE technology appraisal guidance 477. 

    Withdrawn guidance

  7. SQ HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (terminated appraisal) (TA834)

    This guidance has been updated and replaced by NICE technology appraisal guidance 1045.

    Withdrawn guidance

  8. Ruxolitinib for treating acute graft versus host disease refractory to corticosteroids (terminated appraisal) (TA839)

    This guidance has been updated and replaced by NICE technology appraisal guidance 1054.

    Withdrawn guidance

  9. Drotrecogin alfa (activated) for severe sepsis (TA84)

    November 2011 On 25 October 2011, Eli Lilly and Company announced the withdrawal of its Xigris (drotrecogin alfa [activated]) product in all markets following results of the PROWESS–SHOCK study, which showed the study did not meet the primary endpoint of a statistically significant reduction in 28-day all-cause mortality in patients with septic shock. The company is working with regulatory agencies on this withdrawal, and is in the process of notifying healthcare professionals and clinical trial investigators. As a result of this, NICE has withdrawn its guidance on the use of drotrecogin alfa (activated) for severe sepsis.

    Withdrawn guidance

  10. Diabetes (type 2) - rosiglitazone (TA9)

    This guidance has been replaced by NICE technology appraisal guidance 63.

    Withdrawn guidance

  11. Clopidogrel and modified-release dipyridamole in the prevention of occlusive vascular events (TA90)

    This guideline has been updated and replaced by NICE technology appraisal 210.

    Withdrawn guidance

  12. Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer (TA909)

    This guidance has been updated and replaced by NICE technology appraisal guidance 1103.

    Withdrawn guidance

  13. Paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan for second-line or subsequent treatment of advanced ovarian cancer (TA91)

    This guidance has been updated and replaced by NICE technology appraisal guidance 389.

    Withdrawn guidance

  14. Immunosuppressive therapy for renal transplantation in adults (TA85)

    This guidance has been updated and replaced by NICE technology appraisal guidance 481.

    Withdrawn guidance

  15. Mobocertinib for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy (TA855)

    NICE has withdrawn this guidance. Takeda will stop marketing mobocertinib (Exkivity) and its marketing authorisation has been withdrawn. Healthcare professionals should discuss alternative treatment options with people currently having mobocertinib.  

    Withdrawn guidance